Navigation Links
Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Results of the Phase 2 clinical trial of R788 (fostamatinib disodium) in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma (NHL) will be presented today at a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting. The results affirm preliminary reports that Rigel's oral Syk inhibitor is well-tolerated by these patients and shows therapeutic benefit in patients suffering from diffuse large B-Cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Rigel will host a conference call today at 4:00 p.m. PST to discuss these results (see conference call details below).

"Despite the fact that the patients enrolled in this trial had advanced disease and had failed treatment with marketed therapies, a significant number of them were particularly responsive to Syk inhibition with R788," said Jonathan Friedberg, M.D., M.S.Sc., Associate Professor of Medicine, James P. Wilmot Cancer Center, University of Rochester and lead investigator for the clinical trial. "I am encouraged by this data and look forward to conducting additional trials of R788, particularly in patients with DLBCL and CLL/SLL types of non-Hodgkin's lymphomas," he added.


              Phase 2 Results: R788 in NHL Patients - 200 mg bid

                                       Patients      Overall     % Patients
    NHL Type                        (total n=68)     Response     Responding
    DLBCL                                23               5           22%
    Follicular NHL                       21               2           10%
    Other NHL*                           24
      - CLL/SLL                          11               6           55%
      - MCL                               9               1           11%

    * Other NHL patients included 11 with CLL/SLL, 9 with Mantle cell NHL, 1
    
'/>"/>
SOURCE Rigel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
2. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
4. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
(Date:7/25/2014)... San Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and ... MaaS360 Market, and will leverage the MaaS360 WorkPlace ... corporate data. , Splashtop Business and Splashtop Enterprise offer ... using any device. High performance, ease of ...
(Date:7/25/2014)... July 25, 2014 Garth Brooks Chicago ... the Allstate Arena in Rosemont. Garth Brooks was one of ... released his first single in 1989. Since "Much Too Young (To ... the shows from the Tulsa, Okl. native and in the years ... see him back on a stage and in the recording studio. ...
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Ross A. ... has been invited to join the exclusive Obagi Clinical ... leading facial plastic surgeons, plastic surgeons and dermatologists. ... this exclusive Advisory Board of thought leaders held its ... the meeting was to give Obagi the opportunity to ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
... $1.1 million grant to a team of scientists at the ... technology for studying the link between human health and disease ... body. The grant is one of 14 awarded nationwide ... the Human Microbiome Project. The human microbiome consists of beneficial ...
... HealthDay Reporter , TUESDAY, Sept. 14 (HealthDay News) -- ... accurate decisions in all aspects of life, new findings suggest. ... the journal Current Biology theorize that action games ... drawn from their senses in decision-making, a skill known as ...
... , TUESDAY, Sept. 14 (HealthDay News) -- Nearly half ... payments from companies that make orthopedic devices such as artificial ... articles on such devices in medical journals, a new study ... who read the articles aren,t aware of conflicts of interest ...
... Researchers at Children,s Hospital Boston have developed a ... North Carolina at Chapel Hill to engage health care ... safety and real-time pharmacovigilance. The application, "MedWatcher," allows users ... official alerts from the Food and Drug Administration (FDA), ...
... today (14 September 2010), shows that the watercress compound is ... plays a critical role in cancer development. As tumours ... send out signals which make surrounding normal tissues grow new ... nutrients. The research, led by Professor Graham Packham ...
... ROCKVILLE, Maryland, September 14, 2010 Neuralstem, Inc. ... stem cells survived in rat brains affected by ... animals showed significant improvement in some motor skill ... of Adherent Human Neural Stem Cells To Reverse ...
Cached Medicine News:Health News:New research technology to target human gut bacteria 2Health News:Action-Packed Video Games May Be Good for You After All 2Health News:Action-Packed Video Games May Be Good for You After All 3Health News:Medical Study Authors Often Fail to Disclose Industry Ties 2Health News:New iPhone app, 'MedWatcher,' to support real-time drug safety surveillance 2Health News:Watercress may 'turn off' breast cancer signal 2Health News:Neuralstem stem cells survive and differentiate into neurons in rats with stroke 2
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... (Nasdaq: ERES ), a global provider of ... device industries, today announced that Michael McKelvey will be ... Officer and a director of ERT.  The Company,s Board ...  Dr. McKelvey will continue in his current position until ...
... Sept. 10 Covance Inc. (NYSE: CVD ) ... Global Healthcare Conference on Tuesday, September 14, 2010 at 2:10 ... presentation at www.covance.com .  In order to register and ... Covance, with headquarters in Princeton, New Jersey, is ...
Cached Medicine Technology:ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 2ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 3
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
Medicine Products: